Lilly Asia Ventures — 2022 Investments
1 investments dated 2022 · listed companies and verified rows first · show all
ArriVent BioPharmaNASDAQ: AVBPDec 2022
Clinical-stage biopharmaceutical company focused on identifying, developing and commercializing differentiated medicines for cancer patients.
BiotechMedical DevicesNewtown Square, US
Brent Rice(Chief Commercial Officer)Jason Zhang(Director)Cong Xu(Director)Zhengbin (Bing) Yao(Executive Officer, Director)Stuart Lutzker(Director)
PartnerHongbo Lu· solo GP
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.